Product Name: PDGFRA (759-765) pY762
Product Number: PE-04AKV95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: PDGFRA (759-765) pY762

Product Use: Services as a blocking peptide for use with the PDGFRa-pY762 rabbit polyclonal antibody (Cat. No.: AB-PK758) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain near subdomain VI. This is the major in vivo phosphorylation sites in PDGFRa. Phosphorylation induces interaction with CDK6 and CRKL.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RSL-pY-DRP

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1160.19 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: PDGFRA - pY762 phosphosite-specific antibody (Cat. No.: AB-PK758)

Scientific Background: PDGFRA is a receptor protein-tyrosine kinase in the TK family and PDGFR group. It acts as a cell surface receptor for platelet-derived growth factors PDGFA, PDGFB, and PDGFC. This kinase is highly expressed and widely distributed in most tested human tissues. PDGFRA can mediate cell survival, proliferation, embryonic development, chemotaxis, development of the mucosal layer of the gastrointestinal tract, intestinal villi development, wound healing, and platelet activation. The response of PDGFRA depends on whether it homodimerizes or heterodimerizes with PDGFRB. The heterodimer will phosphorylate PLCG1, PTPN11, and PIK3R1. Protein interactions are induced with phosphorylation of Y572 and Y574 (with Src), Y720 and Y754 (with SHP2), Y731 and Y742 (with PIK3R1), Y762 (with CDK6 & CrkL), and Y988 and Y1018 (with PLCg1). Aberrant expression of PDGFRA has been linked to developmental abnormalities and has been implicated in multiple disease states in humans. Widespread expression of PDGFRa occurs in renal cell types involved in fibrotic and sclerosing processes. PDGFRA induces fibrosis in the repair phase of inflammatory bowel disease and may be involved in the active inflammatory phase. PDGFRA is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. PDGFRA has also been linked with the development of atypical chronic myelogenous leukemia, glioblastoma multiforme (GM), melanomas, lung neuroendocrine carcinomas and gastrointestinal stromal cancers. PDGFRA is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. PDGFRA is linked to Gastrointestinal Stromal tumours (GANT, GIST), which are soft tissue sarcomas growing from the stomach, intestines, or rectum. A constitutively active PDGFRA can be induced with a V561D, N659K, D842V, or D842Y, mutation, or with the deletion of 842-845, or deletion of 845-848.